Physician profile
Mark Takemura
NPI 1487721189
$634.89
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $544 · 2020: $41.36 · 2021: $49.94.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $178.64 | 2019-2020 | |
| Gilead Sciences, INC. | $125.00 | 2019 | |
| Allergan, INC. | $81.29 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.15 | 2019 | |
| Intercept Pharmaceuticals, INC. | $38.96 | 2019 | |
| Pfizer INC. | $38.24 | 2019 | |
| Janssen Biotech, INC. | $33.54 | 2019 | |
| Ironwood Pharmaceuticals, INC | $23.00 | 2019 | |
| Ferring Pharmaceuticals INC. | $18.13 | 2020 | |
| Alnylam Pharmaceuticals INC. | $17.68 | 2021 | |
| Celgene Corporation | $16.81 | 2021 | |
| Redhill Biopharma INC. | $15.45 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Takemura listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.